Back to top
more

BioCryst Pharmaceuticals (BCRX)

(Delayed Data from NSDQ)

$8.99 USD

8.99
8,882,690

+0.04 (0.45%)

Updated Jun 18, 2026 04:00 PM ET

After-Market: $8.98 -0.01 (-0.11%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.00%
2Buy18.14%
3Hold10.18%
4Sell5.72%
5Strong Sell3.11%
S&P50011.49%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 247)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

AstraZeneca's Cancer Drug Lynparza Positive in Phase III

by Zacks Equity Research

AstraZeneca plc (AZN) announced positive results from phase III SOLO-2 study which support the potential benefit of marketed drug Lynparza (olaparib) as a maintenance therapy in relapsed ovarian cancer.

    Zacks Equity Research

    Arena Pharmaceuticals (ARNA) Posts Q4 Earnings, Revenues Up

    by Zacks Equity Research

    Arena Pharmaceuticals, Inc. (ARNA) reported earnings of 16 cents per share in the fourth quarter of 2016, as against the year-ago loss of 13 cents and the Zacks Consensus Estimate of a loss of 9 cents.

      Zacks Equity Research

      BioCryst Pharmaceuticals (BCRX) Shares March Higher, Can It Continue?

      by Zacks Equity Research

      BioCryst Pharmaceuticals, Inc. (BCRX) has been on the move lately as the stock has risen by 46.8% in the past four weeks, and it is currently trading well above its 20-Day SMA

        Arpita Dutt headshot

        After Valeant, Here are 5 Drug Stocks Bill Ackman Should Buy Instead

        by Arpita Dutt

        With Bill Ackman finally deciding to exit Valeant (VRX), here is a look at 5 Zacks Rank #1 and #2 drug stocks that the billionaire investor could consider buying.

          Zacks Equity Research

          Adamis (ADMP) Shows Strength: Stock Gains 6.7% in Session

          by Zacks Equity Research

          Adamis Pharmaceuticals Corporation (ADMP) moved big last session, as its shares rose over 6% on the day

            Zacks Equity Research

            Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals (BCRX) Stock?

            by Zacks Equity Research

            Investors in BioCryst Pharmaceuticals, Inc. (BCRX) need to pay close attention to the stock based on moves in the options market lately.

              Zacks Equity Research

              Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals (BCRX) Stock?

              by Zacks Equity Research

              Investors in shares of BioCryst Pharmaceuticals, Inc. (BCRX) need to pay close attention to the stock based on moves in the options market lately.

                Zacks Equity Research

                3 Biotechs Looking Good this Earnings Season

                by Zacks Equity Research

                A number of biotech companies are seeing improvements in their financial results.

                  Zacks Equity Research

                  Can The Uptrend Continue for BioCryst Pharmaceuticals (BCRX)?

                  by Zacks Equity Research

                  Investors certainly have to be happy with BioCryst Pharmaceuticals, Inc. (BCRX) and its short term performance.